IDN5109, a taxane with oral bioavailability and potent antitumor activity

Cancer Research

Volumn 60, Issue 4, 2000, Pages 842-846

  Nicoletti, Maria Ines ^a   Colombo, Tina ^b   Rossi, Cosmo ^c   Monardo, Caterina ^c   Stura, Stefania ^c   Zucchetti, Massimo ^b   Riva, Antonella ^d   Morazzoni, Paolo ^d   Donati, Maria Benedetta ^c   Bombardelli, Ezio ^d   D'Incalci, Maurizio ^b   Giavazzi, Raffaella ^a  

^a MARIO NEGRI INST PHARMACOL RES   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c Laboratorio Angela Valenti dei Fattori Genetici e Ambientali di Rischio Trombotico   (Italy)

^d INDENA S P A   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P; ORTATAXEL; PACLITAXEL; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SENSITIVITY; FEMALE; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; TUMOR REGRESSION;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; BRIDGED COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MICE; MICE, NUDE; OVARIAN NEOPLASMS; PACLITAXEL; TAXOIDS;

EID: 17344393983     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. McGuire, W. P., Rowinsky, E. K., Rosenshein, N. B., Grumbine, F. C., Ettinger, D. S., Armstrong, D. K., and Donehower, R. C. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann. Intern. Med., 111: 273-279, 1989.
2. Runowicz, C. D., Wiernik, P. H., Einzig, A. I., Goldberg, G. L., and Horwitz, S. B. Taxol in ovarian cancer. Cancer (Phila.), 71: 1591-1596, 1993.
3. Gianni, L., Munzone, E., Capri, G., Villani, F., Spreafico, C., Tarenzi, E., Fulfaro, F., Caraceni, A., Martini, C., Laffranchi, A., Valagussa, P., and Bonadonna, G. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J. Natl. Cancer Inst., 87: 1169-1175, 1995.
4. Einzig, A. I., Hochster, H., Wiernik, P. H., Trump, D. L., Dutcher, J. P., Garowski, E., Sasloff, J., and Smith, T. J. A Phase II study of Taxol in patients with malignant melanoma. Investig. New Drugs, 9: 59-64, 1991.
5. Murphy, W. K., Fossella, F. V., Winn, R. J., Shin, D. M., Hynes, H. E., Gross, H. M., Davilla, E., Leimert, J., Dhingra, H., Raber, M. N., Krakoff, I. H., and Hong, W. K. Phase II study of Taxol in patients with untreated advanced non-small-cell lung cancer. J. Natl. Cancer Inst., 85: 384-388, 1993.
6. Rowinsky, E. K., and Donehower, R. C. Paclitaxel (Taxol). N. Engl. J. Med., 332: 1004-1014, 1995.
7. Ojima, I., Park, Y. H., Sun, C-M., Fenoglio, I., Appendino, G., Pera, P., and Bernacki, R. J. Structure-activity relationships of new taxoids derived from 14 β-hydroxy-10-deacetylbaccatin III. J. Med. Chem., 37: 1408-1410, 1994.
8. Ojima, I., Slater, J. C., Kuduk, S. D., Takeuchi, C. S., Gimi, R. H., Sun, C-M., Park, Y. H., Pera, P., Veith, J. M., and Bernacki, R. J. Syntheses and structure-activity relationships of taxoids derived from 14 β-hydroxy-10-deacetyl-baccatin III. J. Med. Chem., 40: 267-278, 1997.
9. McLaughlin, J. L., Miller, R. W., Powell, R. G., and Smith, C. R., Jr. 19-hydroxy-baccatin III, 10-deacetylcephalomannine, and 10-deacetyltaxol: new antitumor taxanes from Taxus wallichiana. J. Nat. Prod. (Lloydia), 44: 312-319, 1981.
10. Appendino, G., Gariboldi, P., Gabetta, B., Pace, R., Bombardelli, E., and Viterbo, D. 14 β-hydroxy-10-deacetyl-baccatin III, a new taxane from Himalayan yew (Taxus wallichiana zucc.), J. Chem. Soc. Perkin Trans, I: 2925-2929, 1992.
11. Distefano, M., Scambia, G., Ferlini, C., Gaggini, C., De Vincenzo, R., Riva, A., Bombardelli, E., Ojima, I., Fattorossi, A., Panici, P. B., and Mancuso, S. Anti-proliferative activity of a new class of taxanes ( 14β-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells. Int. J. Cancer, 72: 844-850, 1997.
12. Sparreboom, A., van Asperen, J., Mayer, U., Schinkel, A. H., Smit, J. W., Meijer, D. K. F., Borst, P., Nooijen, W. J., Beijnen, J. H., and van Tellingen, O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA, 94: 2031-2035, 1997.
13. Meerum Terwogt, J. M., Beijnen, J. H., ten Bokkel Huinink, W. W., Rosing, H., and Schellens, J. H. M. Co-administration of cyclosporin enables oral therapy with paclitaxel. Lancet. 352: 285, 1998.
14. van Asperen, J., van Tellingen, O., Sparreboom, A., Schinkel, A. H., Borst, P., Nooijen, W. J., and Beijnen, J. H. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br. J. Cancer, 76: 1181-1183, 1997.
15. Decreto Legge No. 116, Gazzetta Ufficiale, Suppl. 40, Feb. 18, 1992.
16. Circolare No. 8, Gazzetta Ufficiale, July, 1994.
17. European Economic Community Council Directive 86/609. Official Journal, Legislation 358, 1; December 12, 1987.
18. Guide for the Care and Use of Laboratory Animals. United States National Research Council, 1996.
19. Massazza, G., Tomasoni, A., Lucchini, V., Allavena, P., Erba, E., Colombo, N., Mantovani, A., D'Incalci, M., Mangioni, C., and Giavazzi, R. Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy. Int. J. Cancer, 44: 494-500, 1989.
20. Valoti, G., Nicoletti, M. I., Pellegrino, A., Jimeno, J., Hendriks, H., D'Incalci, M., Faircloth, G., and Giavazzi, R. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin. Cancer Res., 4: 1977-1983, 1998.
21. Belotti, D., Rieppi, M., Nicoletti, M. I., Casazza, A. M., Fojo, T., Taraboletti, G., and Giavazzi, R. Paclitaxel (Taxol) inhibits motility of paclitaxel-resistant human ovarian carcinoma cells. Clin. Cancer Res., 2: 1725-1730, 1996.
22. Colombo, T., Frapolli, R., Bombardelli, E., Morazzoni, P., Riva, A., D'Incalci, M., and Zucchetti, M. High-performance liquid chromatographic assay for the determination of the novel taxane derivative IDN5109 in mouse plasma. J. Chromatogr. B Biomed. Appl., 736: 135-141, 1999.
23. Sacchi-Landriano, G., Guardabasso, V., and Rocchetti, M. NL-FIT: a computer program for non-linear fitting. Comput. Programs Biomed., 16: 35-42, 1983.
24. van Asperen, J., Schinkel, A. H., Beijnen, J. H., Nooijen, W. J., Borst, P., and van Tellingen, O. Altered pharmacokinetics of vinblastine in mdr-la P-glycoprotein-deficient mice. J. Natl. Cancer Inst., 88: 994-999, 1996.
25. Horwitz, S. B., Cohen, D., Rao, S., Ringel, I., Shen, H-J., and Yang, C-P. H. Taxol: mechanisms of action and resistance. J. Natl. Cancer Inst. Monogr., 15: 55-61, 1993.
26. Rowinsky, E. K., Cazenave, L. A., and Donehower, R. C. Taxol: a novel investigational antimicrotubule agent. J. Natl. Cancer Inst., 82: 1247-1259, 1990.
27. Huizing, M. T., Keung, A. C., Rosing, H., van der Kuij, V., ten Bokkel Huinink. W. W., Mandjes, J. M., Dubbelman, A. C., Pinedo, H. M., and Beijnen, J. H. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J. Clin. Oncol., 11: 2127-2135, 1993.
28. Gianni, L., Kearns, C. M., Giani, A., Capri, G., Vigano, L., Lacatelli, A., Bonadonna, G., and Egorin, M. J. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J. Clin. Oncol., 13: 180-190, 1995.
29. Polizzi, D., Pratesi, G., Tortoreto, M., Supino, R., Riva, A., Bombardelli, E., and Zunino, F. A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts. Cancer Res., 59: 1036-1040, 1999.